SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.

EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

Username

Password

Confirm Password

Work E-mail Address

Confirm E-mail Address

Occupation

Other

Full Name LEAVE THIS BLANK

Payment Information We accept all major credit cards

Card Number

Expiration Date

CVC

Discount Code

I want to receive updates from celltelligence.com.

By selecting this, I agree to receive emails from celltelligence.com.

Processing...

Already have an account? Log in here

RETURN TO HOME

TCR

September 28, 2021

Ziopharm’s TCR-T Program Pushed Back to H1 2022; Ziopharm Sheds Over 50% of Its Workforce

Here is a brief preview of this blast: On Monday, September 27, Ziopharm announced (press release) that they have reduced their staffing levels by over 50% (eliminating 60 positions) while extending their cash runway into H1 2023. Additionally, management confirmed that the first patient from the Ph1/2 TCR-T Library trial is expected to be dosed in H1 2022. Below, Celltelligence provides insights on Ziopharm’s TCR-T program delay, in-house manufacturing strategy, and if the company's latest measures will regain shareholders’ confidence.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.